JPMorgan International Research Enhanced Equity ETF
JPMorgan · Tracks (actively managed — no index) · Inception Oct 28, 1992
Composite score
Based on a 0.24% expense ratio.
Based on $11.13B in net assets.
Top-10 holdings represent 16.4% of net assets.
International Developed base · ETF wrapper · 2.70% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use JIRE in our tools
Tool · Cost
Compare JIRE's fee against another fund
Compounds the 0.24% expense ratio against a peer over decades.
Tool · Overlap
Compare JIRE's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar International Developed funds.
Tool · TLH
Find a tax-loss harvesting partner for JIRE
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | ASML Holding NV | 3.17% |
| 2 | AstraZeneca plc | 2.06% |
| 3 | Siemens AG | 1.67% |
| 4 | Shell plc | 1.60% |
| 5 | Allianz SE | 1.43% |
| 6 | HSBC Holdings plc | 1.43% |
| 7 | Nestle SA | 1.40% |
| 8 | Roche Holding AG | 1.27% |
| 9 | Banco Santander SA | 1.21% |
| 10 | Novartis AG | 1.20% |
Compare JIRE with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open JIRE at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.